Beyond Hormones: Non-Hormonal Medication Options for Perimenopausal Insomnia

Key Points Summary

✓ SSRIs and SNRIs: Can help both mood symptoms and vasomotor symptoms that disrupt sleep
✓ Gabapentin: Evidence for reducing hot flashes and improving sleep, particularly useful when neuropathic pain coexists
✓ Fezolinetant: Newer neurokinin 3 receptor antagonist targeting the hot flash pathway directly
✓ Prolonged-release melatonin: Considered first-line pharmacologic option for women 55+ due to favorable safety
✓ Conventional hypnotics: Can be appropriate short-term but problematic for long-term use

Hormone therapy isn’t right for everyone. Some women have contraindications, a history of estrogen-receptor-positive breast cancer, blood clots, or certain cardiovascular conditions. Others simply prefer not to use hormones. And for some, hormonal approaches help but don’t fully resolve the sleep problem.

Fortunately, options exist beyond hormones. The evidence base varies, and none of these is a perfect solution, but understanding what’s available can help you and your provider make informed decisions.

Antidepressants for Vasomotor Symptoms and Sleep

This might seem like an odd category, antidepressants for sleep?, but several SSRIs and SNRIs have been studied specifically for menopausal symptoms, including sleep disruption.

Paroxetine (Brisdelle) is FDA-approved specifically for vasomotor symptoms at a low dose (7.5 mg), lower than typical antidepressant doses. It can reduce hot flash frequency and severity, which in turn may improve sleep.[1]

Venlafaxine and desvenlafaxine (SNRIs) have also shown efficacy for vasomotor symptoms in randomized trials. Desvenlafaxine 100-150 mg reduced hot flash frequency by about 60% in some studies.[1]

Escitalopram has evidence for reducing hot flashes, though perhaps less robustly than the SNRIs.

The sleep benefits of these medications come primarily through vasomotor symptom reduction, though some women also experience improvement in the mood and anxiety symptoms that can disrupt sleep during perimenopause. For women who have both significant hot flashes and mood symptoms, an SSRI or SNRI might address both with one medication.

The downsides: SSRIs and SNRIs have their own side effects, including sexual dysfunction, weight changes, and for some people, initially worsened sleep. They’re not a good fit for everyone.

Gabapentin

Gabapentin is an anticonvulsant medication that has found many uses beyond seizures, including hot flash treatment.

Research shows gabapentin can reduce hot flash frequency and severity, with corresponding improvements in sleep.[1] A typical dose for hot flashes is 900 mg daily, though lower doses can also be helpful.

Gabapentin has some advantages worth noting. It’s sedating, so when taken at bedtime, the sedation becomes a feature rather than a side effect. It can help with certain types of pain, particularly neuropathic pain, so for women who have hot flashes, sleep disruption, and pain issues, it might address multiple problems.

The downsides: daytime drowsiness, dizziness, and cognitive dulling can be problematic, especially at higher doses. Some people gain weight. It needs to be tapered when discontinuing rather than stopped abruptly. There is also concern about cognitive dulling increasing the risk for dementia when used at higher doses or for a longer time. 

Fezolinetant: A Newer Approach

Fezolinetant (brand name Veozah) represents something genuinely new: a medication designed specifically to target the mechanism underlying hot flashes.

Remember those KNDy neurons I mentioned earlier, the hypothalamic neurons that become overactive during menopause and trigger hot flashes? Fezolinetant works by blocking the neurokinin 3 receptors on these neurons.[2]

In clinical trials, fezolinetant reduced moderate-to-severe hot flashes by about 60% compared to placebo. It’s FDA-approved for vasomotor symptoms.[2]

Because it addresses hot flashes at their source rather than compensating downstream, fezolinetant might improve sleep through multiple mechanisms, not just by preventing the nighttime awakenings from hot flashes, but potentially through the broader effects of normalizing the dysfunctional hypothalamic circuitry.

This medication is newer, so long-term data is limited. The most significant concern is liver toxicity, which requires monitoring. It’s not first-line for most women, but it’s an option when other approaches haven’t worked or aren’t suitable.

Prolonged-Release Melatonin

Melatonin is familiar to most people as an over-the-counter sleep supplement, but the evidence and recommendations are more nuanced than marketing suggests.

Standard (immediate-release) melatonin helps with sleep onset but typically wears off after a few hours. For perimenopausal insomnia, where the problem is often staying asleep rather than falling asleep, immediate-release melatonin may not address the main issue.

Prolonged-release melatonin (available by prescription in some countries, or as extended-release OTC formulations) maintains melatonin levels through the night and has more evidence for improving overall sleep quality.[3]

For women aged 55 and older, prolonged-release melatonin is considered a first-line pharmacologic option for insomnia by some guidelines, primarily because its safety profile is favorable compared to other sleep medications.[3] It doesn’t carry the cognitive risks, fall risks, or dependence potential of benzodiazepines or Z-drugs.

The effect size is modest, don’t expect dramatic results, but for some women, it makes a meaningful difference with minimal downside.

The Problem with Conventional Sleep Medications

I want to address benzodiazepines (like temazepam, lorazepam) and “Z-drugs” (like zolpidem, eszopiclone) because many women have used them or been offered them for perimenopausal insomnia.

These medications work. They will help you fall asleep and stay asleep, at least initially. That’s not in question.

The problems are several:

Tolerance develops. Over time, you need higher doses for the same effect. What worked at first stops working.

Dependence develops. These medications are habit-forming. Stopping them after regular use causes rebound insomnia that’s often worse than the original problem, creating a trap.

Sleep quality is abnormal. Both benzodiazepines and Z-drugs suppress slow-wave (deep) sleep.[4] You may sleep more hours but wake feeling less rested than you should.

Cognitive risks. Particularly concerning for midlife and older women, these medications are associated with increased fall risk, memory impairment, and possible (though debated) increased dementia risk with long-term use.

They don’t address underlying causes. You’re suppressing the symptom without touching what’s driving it. When you stop, the problem is still there, often worse, because you haven’t done the work to address perpetuating factors.

For short-term, occasional use during a crisis? These medications have a role. For the ongoing treatment of chronic perimenopausal insomnia? They’re not a good solution. You deserve better.

Trazodone: A Common but Limited Option

Trazodone deserves mention because it’s frequently prescribed for sleep, even though it’s technically an antidepressant.

At low doses (25-100 mg), trazodone is sedating without significant antidepressant effects. It doesn’t have the same dependence risk as benzodiazepines or Z-drugs, and it doesn’t suppress deep sleep in the same way.

The limitations: the evidence specifically for menopausal insomnia is thin. Side effects include morning grogginess, dry mouth, and rarely, priapism in men (a painful sustained erection, worth mentioning if you’re considering it for a male partner). It’s reasonable to try but shouldn’t be considered a definitive solution.

How These Fit Together

For women who can’t or prefer not to use hormone therapy, a reasonable approach might be:

First-line: CBT-I (behavioral treatment, works regardless of cause), plus addressing any underlying mood disorder if present.

If vasomotor symptoms are prominent: Consider an SSRI/SNRI (especially if mood is also an issue), gabapentin (especially if pain is also an issue), or fezolinetant (especially if other options haven’t worked).

For general sleep support: Prolonged-release melatonin is low-risk and worth trying, particularly for women 55+.

Conventional hypnotics: Reserve for short-term use during acute stress or as occasional rescue, not for ongoing management.

This isn’t a rigid algorithm, individual circumstances matter enormously. But it gives a framework for thinking about options.

What This Means for You

If you’re navigating perimenopausal insomnia and hormones aren’t the right path for you, don’t despair. Options exist.

Work with a provider who understands sleep medicine and is willing to discuss the full range of approaches, not just the easiest prescription. Consider whether vasomotor symptoms, mood, pain, or other factors are driving your sleep disruption, because that guides which options make most sense.

And remember: medications are usually most effective when combined with behavioral approaches. CBT-I, sleep hygiene, stress management, and lifestyle optimization aren’t just things to try first, they’re the foundation that makes any medication work better.

This post is part of a series on sleep, hormones, and the menopausal transition. Next, we’ll explore the integrative toolkit, supplements, nutrients, and lifestyle strategies that support sleep during perimenopause.  Please work with a licensed medical professional before adding any medications. 

References

1. Chang JG, Lewis MN, Wertz MC. Managing Menopausal Symptoms: Common Questions and Answers. American Family Physician. 2023. https://www.aafp.org/pubs/afp/issues/2023/0600/managing-menopausal-symptoms.html
2. Maki PM, Panay N, Simon JA. Sleep Disturbance Associated With the Menopause. Menopause. 2024;31(8):724-733. doi:10.1097/GME.0000000000002386. https://pubmed.ncbi.nlm.nih.gov/38954663/
3. Proserpio P, Marra S, Campana C, et al. Insomnia and Menopause: A Narrative Review on Mechanisms and Treatments. Climacteric. 2020;23(6):539-549. doi:10.1080/13697137.2020.1799973. https://pubmed.ncbi.nlm.nih.gov/32880197/
4. Schüssler P, Kluge M, Adamczyk M, et al. Sleep After Intranasal Progesterone vs. Zolpidem and Placebo in Postmenopausal Women: A Randomized, Double-Blind Cross Over Study. Psychoneuroendocrinology. 2018;92:81-86. doi:10.1016/j.psyneuen.2018.04.001. https://pubmed.ncbi.nlm.nih.gov/29635109/